← Leaderboards
Pin Wang
University Of Southern California
$5,634,307
Attributed
$8,199,716
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2006–16$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$8,199,716 · 5
By mechanism
R01$6,543,084 · 3
P01$1,466,112 · 1
R21$190,520 · 1
Top collaborators
- Zelig Eshhar4 shared
- Amer M Najjar4 shared
- Richard W Roberts4 shared
- David Steiner4 shared
- Terry Torao Takahashi4 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCancer ImmunotherapyNovel StrategiesLentivirus VectorMalignant NeoplasmsModificationCellsIn VitroLightHematopoietic Stem CellsImmune ResponseIn SituGene Delivery SystemDesignGenesBaseAntibodiesAnimal ModelBinding (Molecular Function)AffinityEngineeringGene DeliveryCancer TherapyClinical Trials
Grant awards (19)
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.$483,404
R01 · FY2016 · EB
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.$461,820
R01 · FY2015 · EB
SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)$443,825
R01 · FY2015 · CA
SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)$439,344
R01 · FY2014 · CA
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.$426,075
R01 · FY2014 · EB
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity$307,707
P01 · FY2014 · CA · contact PI
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.$458,203
R01 · FY2013 · EB
SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)$433,973
R01 · FY2013 · CA
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity$274,100
P01 · FY2013 · CA · contact PI
SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)$472,782
R01 · FY2012 · CA
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity$291,596
P01 · FY2012 · CA · contact PI
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity$291,597
P01 · FY2011 · CA · contact PI
Targeting lentiviruses to infect chosen cells$603,733
R01 · FY2010 · AI · contact PI
Optimization of MART-1 TCR Gene Transfer for Anti-Melanoma Immunity$301,112
P01 · FY2010 · CA · contact PI
Targeting lentiviruses to infect chosen cells$592,071
R01 · FY2009 · AI · contact PI
Targeting lentiviruses to infect chosen cells$574,827
R01 · FY2008 · AI · contact PI
Targeting lentiviruses to infect chosen cells$568,888
R01 · FY2007 · AI · contact PI
Targeting lentiviruses to infect chosen cells$584,139
R01 · FY2006 · AI · contact PI
Retroviral Transduction Using Acoustic Waves$190,520
R21 · FY2006 · EB · contact PI